Company Listing
Prosensa

Prosensa is using exon-skipping technology to develop oligonucleotide based therapeutics and correct gene expression in diseases with large unmet medical needs, in particular neuromuscular disorders. The company is developing a medicine for Duchenne Muscular Dystrophy, a lethal childhood genetic disease that has no curative therapy. Prosensa went public in June 2013 and was acquired by BioMarin for up to $840 million in February 2015.

BACK
Location
Leiden, Netherlands

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Company Listing

Prosensa is using exon-skipping technology to develop oligonucleotide based therapeutics and correct gene expression in diseases with large unmet medical needs, in particular neuromuscular disorders. The company is developing a medicine for Duchenne Muscular Dystrophy, a lethal childhood genetic disease that has no curative therapy. Prosensa went public in June 2013 and was acquired by BioMarin for up to $840 million in February 2015.

Location
Leiden, Netherlands
BACK
 
Copyright Abingworth 2017